Literature DB >> 21173871

On diagnostic blocks for lumbar zygapophysial joint pain.

Nikolai Bogduk1.   

Abstract

Diagnostic blocks are used to identify patients with back pain stemming from their lumbar zygapophysial joints. Single, diagnostic blocks have an unacceptably high false positive rate. As well, comparative local anaesthetic blocks lack validity because the prevalence of the condition is low. Relying on 50% relief following single-diagnostic blocks does not provide a valid diagnosis. Placebo-controlled blocks are the only available valid means of establishing a diagnosis of lumbar zygapophysial joint pain.

Entities:  

Year:  2010        PMID: 21173871      PMCID: PMC2990543          DOI: 10.3410/M2-57

Source DB:  PubMed          Journal:  F1000 Med Rep        ISSN: 1757-5931


Introduction and context

The proposition that the lumbar zygapophysial joints could be a source of low back pain is valid - as a concept. In normal volunteers, experimental noxious stimulation of these joints can produce low back pain and referred pain into the lower limb [1]. The problem lies in how to establish in a given patient if their back pain stems from a zygapophysial joint. Neither medical imaging [2] nor history or physical examination [3-5] provides a means for making the diagnosis. The only method that has gained any traction is diagnostic block. Putatively painful joints can be anaesthetised directly with intra-articular blocks, or indirectly with lumbar medial branch blocks, which anaesthetise the nerves that innervate the joint [1]. Virtually all publications on the yield of intra-articular blocks did not use controls. Only one study used subcutaneous injection of normal saline as a control for intra-articular blocks [6]. For a criterion of 50% relief of pain, the prevalence was 40%; for the criterion of 90% relief of pain, it was 32%. Lumbar medial branch blocks have been more rigorously validated. They protect normal volunteers from experimentally induced pain from the zygapophysial joints [1]. They do not anaesthetise other structures that might be an alternative source of pain [1]. However, without controls, lumbar medial branch blocks have a prohibitively large false positive rate, variously reported as between 25% [7] and 41% [8,9]. One form of control comprises comparative local anaesthetic blocks, in which either a long-acting local anaesthetic or a short-acting local anaesthetic is used, on separate occasions, under double-blind conditions [10]. Comparative blocks have a sensitivity of 100% and a specificity of 65% [10].

Recent advances

At least three schools of thought and practice have arisen. One might be called the pragmatic school. It abjures controlled blocks. Moreover, it argues that it matters not whether patients obtain 50% relief or 80% relief from a diagnostic block, because their response to treatment - with radiofrequency neurotomy - is statistically indistinguishable [11]. This school maintains that imposing rigorous criteria for diagnostic blocks denies worthwhile benefit to patients who would otherwise satisfy less rigorous criteria. Although attractive to some, the evidence for this pragmatic approach is weak. The definition of worthwhile benefit was 50% relief of pain for 6 months [11], which is less than the benchmark for lumbar medial branch neurotomy [12]. Nor has it been shown that 50% relief leads to socially significant improvements in function, and elimination of other health care. The second school insists that comparative blocks are essential, and that the criterion for a positive response be 80% relief of pain. It opposes the pragmatic school, arguing that alternative treatments, less expensive than neurotomy, can be used for patients who do not satisfy the more rigorous criteria [13]. Recently, this school argued that 80% relief was more valid than 50% relief because a greater proportion of patients with 80% relief maintained their response over 2 years [13]. However, whereas this is evidence of the stability of the response, it is not evidence of its validity. The third school might be called the purist, or academic school. It disputes both other schools. Foremost, it argues that single diagnostic blocks are not valid because they have an unacceptably high false positive rate [1,10]. Consequently, patients who report either 50% or 80% relief after a single diagnostic block will include a large proportion with placebo responses. Under these conditions, the correlations reported by the pragmatic school [11] amount to no more than comparing confounded responses to a diagnostic test with questionable outcomes of treatment. The purist school is also at odds with the second school. Comparative blocks have a sensitivity of 100% and a specificity of 65% [10], but the validity of a diagnostic test is not determined simply by its sensitivity and specificity; it is a complex product of sensitivity, specificity, and the prevalence of the condition. Table 1 illustrates the situation.
Table 1.

Outcomes of a diagnostic test illustrating how diagnostic confidence diminishes with prevalence

PrevalenceTestConditionDiagnostic confidence
PresentAbsent
60%Positive60014081%
Negative0260
600400
40%Positive40021066%
Negative0390
400600
20%Positive20028042%
Negative0520
200800
10%Positive10031524%
Negative0585
100900
5%Positive5028215%
Negative0618
50950

A demonstration of the outcomes of a diagnostic test, with a sensitivity of 100% and a specificity of 65%, when applied to a sample of 1000 patients, illustrating how diagnostic confidence diminishes with prevalence. Diagnostic confidence is the certainty with which the investigator can estimate that a positive result is true positive, rather than false positive, and is the number of patients who have the condition and who report a positive response, as a proportion of the total number of positive responses.

For a test with 100% sensitivity, all patients who have the condition are correctly detected. However, with a specificity of 65%, 35% of patients who do not have the condition report a positive result. When the prevalence is high, the number of patients who do not have the condition is low, and the number of false positive results is proportionately low. As a result, most positive responses are true positive, and the investigator can be confident that a given positive response is highly likely to be true positive. For a prevalence of 60% (Table 1), the diagnostic confidence is 81%, that is, a positive result will be correct 4 times out of 5. As the prevalence of the condition diminishes, the number of patients who do not have the condition grows, and the number of false positive responses increases, to the extent that false positive responses outnumber true positive responses. For a prevalence of 20% (Table 1), the diagnostic confidence is only 42%, meaning that more than 1 in 2 positive responses will be false. For a prevalence of 5%, the diagnostic confidence plummets to 15%, meaning that for every 8 positive responses, 7 will be false. A demonstration of the outcomes of a diagnostic test, with a sensitivity of 100% and a specificity of 65%, when applied to a sample of 1000 patients, illustrating how diagnostic confidence diminishes with prevalence. Diagnostic confidence is the certainty with which the investigator can estimate that a positive result is true positive, rather than false positive, and is the number of patients who have the condition and who report a positive response, as a proportion of the total number of positive responses. This is not a problem for cervical medial branch blocks because the prevalence of cervical zygapophysial joint pain is 60% [14], and the diagnostic confidence is 81%. Lumbar zygapophysial joint pain is not that common. The more favourable estimates place its prevalence at about 40%; more critical estimates place it as low as 5% [1,10]. In the case of the former, one in three diagnoses will be wrong; in the case of the latter, seven in eight will be wrong. For these reasons, comparative local anaesthetic blocks are not valid for the diagnosis of lumbar zygapophysial joint pain. The only means by which a practitioner can become confident that their patient actually does have lumbar zygapophysial joint pain is to perform placebo-controlled, diagnostic blocks. Without this measure, practitioners will overestimate the prevalence of lumbar zygapophysial joint pain; an inordinate number of patients will be accorded an incorrect diagnosis and be directed to inappropriate treatment, and the majority of patients treated will fail treatment.

Implications for clinical practice

Purists demand complete relief of pain following placebo-controlled blocks. They seek to provide interventional pain medicine with a respectable, scientific basis, consonant with the standards of thought and practice in other domains of medicine. Pragmatists argue for lesser criteria, and even for the abandonment of blocks and diagnosis altogether. The judgment lies with third-party observers. If blocks are to be disregarded, and all patients are to be treated summarily, observers cannot tell from arbitrary and random behaviour amongst practitioners. Moreover, if there is no demonstrable reduction in the burden of illness, why should they pay for this behaviour? The evidence indicates that lumbar zygapophysial joint pain is uncommon, and under evidence-based practice lumbar medial branch neurotomy should become an uncommon procedure. In contemporary practice, however, questionable outcomes are being achieved by basing treatment on diagnostic tests that lack validity. This behaviour threatens the reputation of interventional pain medicine, and the reimbursement of its procedures. The foremost argument against performing controlled diagnostic blocks, at least in the US, has been that insurers do not pay for controlled blocks. The consequence of such a system is that it pays for inconclusive diagnosis but abjures evidence-based, best practice. Economic modelling, however, has shown that controlled blocks are cost-effective whenever the cost of treatment exceeds the cost of blocks by a factor of 1.5 or more [15]. Whereas this might not apply in the US, it does in other jurisdictions where lumbar medial branch neurotomy is reimbursed as a neurosurgical procedure. Under those conditions, placebo-controlled blocks become mandatory, and remain cost-effective [15].
  14 in total

1.  Controlled zygapophysial joint blocks: the travesty of cost-effectiveness.

Authors:  N Bogduk; S Holmes
Journal:  Pain Med       Date:  2000-03       Impact factor: 3.750

2.  Making sense of the accuracy of diagnostic lumbar facet joint nerve blocks: an assessment of the implications of 50% relief, 80% relief, single block, or controlled diagnostic blocks.

Authors:  Laxmaiah Manchikanti; Sneha Pampati; Kimberly A Cash
Journal:  Pain Physician       Date:  2010 Mar-Apr       Impact factor: 4.965

3.  Clinical predictors of screening lumbar zygapophyseal joint blocks: development of clinical prediction rules.

Authors:  Mark Laslett; Barry McDonald; Charles N Aprill; Hans Tropp; Birgitta Oberg
Journal:  Spine J       Date:  2006 Jul-Aug       Impact factor: 4.166

4.  Prevalence of lumbar facet joint pain in chronic low back pain.

Authors:  L Manchikanti; V Pampati; B Fellows; C E Bakhit
Journal:  Pain Physician       Date:  1999-10       Impact factor: 4.965

5.  The inability of the clinical picture to characterize pain from facet joints.

Authors:  L Manchikanti; V Pampati; B Fellows; A G Baha
Journal:  Pain Physician       Date:  2000-04       Impact factor: 4.965

6.  Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain.

Authors:  A C Schwarzer; S C Wang; N Bogduk; P J McNaught; R Laurent
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

7.  Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study.

Authors:  S M Lord; L Barnsley; B J Wallis; N Bogduk
Journal:  Spine (Phila Pa 1976)       Date:  1996-08-01       Impact factor: 3.468

8.  Lumbar zygapophysial (facet) joint radiofrequency denervation success as a function of pain relief during diagnostic medial branch blocks: a multicenter analysis.

Authors:  Steven P Cohen; Milan P Stojanovic; Matthew Crooks; Peter Kim; Rolf K Schmidt; Cynthia H Shields; Scott Croll; Robert W Hurley
Journal:  Spine J       Date:  2007-06-18       Impact factor: 4.166

9.  The false-positive rate of uncontrolled diagnostic blocks of the lumbar zygapophysial joints.

Authors:  A C Schwarzer; C N Aprill; R Derby; J Fortin; G Kine; N Bogduk
Journal:  Pain       Date:  1994-08       Impact factor: 6.961

10.  Zygapophysial joint blocks in chronic low back pain: a test of Revel's model as a screening test.

Authors:  Mark Laslett; Birgitta Oberg; Charles N Aprill; Barry McDonald
Journal:  BMC Musculoskelet Disord       Date:  2004-11-16       Impact factor: 2.362

View more
  5 in total

Review 1.  Placebo effect in the management of chronic pain.

Authors:  J S Perfitt; N Plunkett; S Jones
Journal:  BJA Educ       Date:  2020-09-03

Review 2.  Role of facet joints in spine pain and image-guided treatment: a review.

Authors:  J L Bykowski; W H W Wong
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

3.  Management of lumbar zygapophysial (facet) joint pain.

Authors:  Laxmaiah Manchikanti; Joshua A Hirsch; Frank Je Falco; Mark V Boswell
Journal:  World J Orthop       Date:  2016-05-18

4.  Prognostic factors in low back pain individuals undergoing steroid and anaesthetic intra-articular facet joint infiltration: a protocol for a prospective, longitudinal, cohort study.

Authors:  João Carlos Rodrigues; Arthur Werner Poetscher; Mario Lenza; Alberto Ofenhejm Gotfryd; Délio Eulálio Martins Filho; Luciano Miller Reis Rodrigues; Rodrigo Gobbo Garcia; Laercio Alberto Rosemberg; Durval do Carmo Santos Barros; Eduardo Noda Kihara Filho; Mario Ferretti; Gilbert Sung Soo Bang
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

5.  Predictors of Pain Recurrence After Lumbar Facet Joint Injections.

Authors:  Wuilker Knoner Campos; Marcelo Neves Linhares; Jamir Sarda; Adair Roberto Soares Santos; Kátia Lin; Alexandra Latini; Roger Walz
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.